
Surrozen, Inc./DE — Investor Relations & Filings
Surrozen, Inc. is a clinical-stage company that discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is pioneering a new class of targeted regenerative antibodies designed to stimulate the body's own repair mechanisms. These therapeutics aim to repair a broad range of tissues and restore organs damaged by serious diseases and injuries, with the goal of unlocking the body's regenerative power.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-05-14 | English | |
| ARS - Surrozen, Inc./DE (0001824893) (Filer) | 2026-04-01 | English | |
| DEF 14A - Surrozen, Inc./DE (0001824893) (Filer) | 2026-04-01 | English | |
| 4 - Surrozen, Inc./DE (0001824893) (Issuer) | 2026-03-26 | English | |
| S-8 - Surrozen, Inc./DE (0001824893) (Filer) | 2026-03-23 | English | |
| S-3 - Surrozen, Inc./DE (0001824893) (Filer) | 2026-03-23 | English |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46301940 | 8-K | 2026-05-14 | English | ||
| 33150029 | ARS - Surrozen, Inc./DE (0001824893) (Filer) | 2026-04-01 | English | ||
| 33149954 | DEF 14A - Surrozen, Inc./DE (0001824893) (Filer) | 2026-04-01 | English | ||
| 33043640 | 4 - Surrozen, Inc./DE (0001824893) (Issuer) | 2026-03-26 | English | ||
| 33016647 | S-8 - Surrozen, Inc./DE (0001824893) (Filer) | 2026-03-23 | English | ||
| 33016643 | S-3 - Surrozen, Inc./DE (0001824893) (Filer) | 2026-03-23 | English | ||
| 33016227 | 8-K - Surrozen, Inc./DE (0001824893) (Filer) | 2026-03-23 | English | ||
| 31920802 | 4 Filing | 2026-02-18 | English | ||
| 31920788 | 4 Filing | 2026-02-18 | English | ||
| 31920763 | 4 Filing | 2026-02-18 | English | ||
| 31920810 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32899184 | 4 - SURROZEN, INC./DE (0001824893) (Filer) | 2026-02-13 | English | ||
| 31920907 | SCHEDULE 13G/A Filing | 2026-02-05 | English | ||
| 31920877 | 4 Filing | 2026-02-03 | English | ||
| 31920884 | SCHEDULE 13G Filing | 2026-02-02 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
NOVOPROTEIN SCIENTIFIC INC.
Develops recombinant proteins and enzymes for life sciences…
|
688137 | CN | Professional, scientific and te… |
|
NOXOPHARM LIMITED
Clinical-stage developer of novel treatments for cancer and…
|
NOX | AU | Professional, scientific and te… |
|
NUFORMIX PLC
Pharmaceutical developer using cocrystal technology to repu…
|
NFX | GB | Professional, scientific and te… |
|
Nurix Therapeutics, Inc.
Clinical-stage biopharma developing protein degradation the…
|
NRIX | US | Professional, scientific and te… |
|
NYRADA INC.
Develops small molecule therapeutics for cardiovascular hea…
|
NYR | AU | Professional, scientific and te… |
|
OLIPASS CORPORATION
An R&D company developing RNA therapeutics using its propri…
|
244460 | KR | Professional, scientific and te… |
|
OmniAb, Inc.
A technology platform for therapeutic antibody discovery us…
|
OABIW | US | Professional, scientific and te… |
|
ONCIMMUNE HOLDINGS PLC
Immunodiagnostics company specializing in antibody and auto…
|
ONC | GB | Professional, scientific and te… |
|
Oncocross Co.,Ltd.
An AI biotechnology firm that develops drugs by predicting …
|
382150 | KR | Professional, scientific and te… |
|
ONCODESIGN
Develops therapeutic and diagnostic solutions for resistant…
|
ALONC | FR | Professional, scientific and te… |
Surrozen, Inc./DE via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34164/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34164 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34164 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34164 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34164}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Surrozen, Inc./DE (id: 34164)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.